Skip to main content
Premium Trial:

Request an Annual Quote

Juvaris to Use Antigen Discovery's Protein Microarray Screening System

NEW YORK (GenomeWeb News) – Juvaris BioTherapeutics will use Antigen Discovery's high-throughput protein microarray screening system to discover disease-specific antigens for use in vaccines, Juvaris said today.

Antigen Discovery will retain rights to diagnostics related to the antigens.

Burlingame, Calif.-based Juvaris said that it will sponsor research for multiple disease targets and pay Antigen Discovery upfront payments. Juvaris will select optimal antigens from Antigen Discovery's efforts to combine with its own adjuvant technology to create highly immunogenic prophylactic and therapeutic vaccines against major unmet medical needs, it said.

Further terms of the alliance were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.